The ruling marks the end of a case that put Alnylam and Pfizer at loggerheads. In its response to the PMCPA, Alnylam accused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results